mRNA 疫苗对奥密克戎变异株流行期间严重急性呼吸道感染（SARI）COVID-19 住院的有效性的估计来自真实世界监测数据，斯洛文尼亚，2022 年 2 月至 3 月。
mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022.
机构信息
Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia.
出版信息
Euro Surveill. 2022 May;27(20). doi: 10.2807/1560-7917.ES.2022.27.20.2200350.
Abstract
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95-96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79-84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
摘要
在 2022 年 2 月至 3 月期间，斯洛文尼亚的 SARS-CoV-2 奥密克戎变体占主导地位，我们使用监测数据估计了 mRNA 疫苗对严重急性呼吸道感染（SARI）COVID-19 的有效性（VE）。在最脆弱的年龄组中，包括 65 岁及以上的人群，与接种两剂疫苗的人群相比，接种三剂疫苗的人群对 SARI COVID-19 的 VE 为 95%（95%CI：95-96%），而接种两剂疫苗的人群为 82%（95%CI：79-84%）。这种保护水平至少持续了 6 个月。
相似文献
1
mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022.mRNA 疫苗对奥密克戎变异株流行期间严重急性呼吸道感染（SARI）COVID-19 住院的有效性的估计来自真实世界监测数据，斯洛文尼亚，2022 年 2 月至 3 月。
Euro Surveill. 2022 May;27(20). doi: 10.2807/1560-7917.ES.2022.27.20.2200350.
2
Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021.基于真实世界监测数据估计的 COVID-19 疫苗对严重急性呼吸道感染（SARI）相关住院的有效性，斯洛文尼亚，2021 年 10 月。
Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101110.
3
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.美国 Delta 和奥密克戎变异株流行期间估计 COVID-19 mRNA 疫苗在孕妇中对有医疗需要的 COVID-19 的有效性。
JAMA Netw Open. 2022 Sep 1;5(9):e2233273. doi: 10.1001/jamanetworkopen.2022.33273.
4
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性：一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
5
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.在加拿大魁北克省，mRNA 疫苗接种者和未接种者中，先前感染 SARS-CoV-2 对奥密克戎变异株再感染的估计保护作用。
JAMA Netw Open. 2022 Oct 3;5(10):e2236670. doi: 10.1001/jamanetworkopen.2022.36670.
6
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.奥密克戎 XBB 谱系为主流行期间，改良二价 mRNA COVID-19 疫苗对≥60 岁人群住院的有效性：VEBIS SARI VE 网络，欧洲，2023 年 2 月至 8 月。
Euro Surveill. 2024 Jan;29(3). doi: 10.2807/1560-7917.ES.2024.29.3.2300708.
7
COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.基于西班牙严重急性呼吸道感染（SARI）哨点监测的 COVID-19 疫苗对因 SARS-CoV-2 住院的有效性：一项基于测试阴性设计的研究。
Influenza Other Respir Viruses. 2022 Nov;16(6):1014-1025. doi: 10.1111/irv.13026. Epub 2022 Jul 26.
8
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
9
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.mRNA 疫苗加强剂对卡塔尔奥密克戎感染的保护效果。
N Engl J Med. 2022 May 12;386(19):1804-1816. doi: 10.1056/NEJMoa2200797. Epub 2022 Mar 9.
10
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
引用本文的文献
1
Real-world effectiveness of COVID-19 vaccines among Colombian adults: A retrospective, population-based study of the ESPERANZA cohort.COVID-19疫苗在哥伦比亚成年人中的真实世界有效性：一项基于人群的ESPERANZA队列回顾性研究。
PLOS Glob Public Health. 2023 Sep 8;3(9):e0001845. doi: 10.1371/journal.pgph.0001845. eCollection 2023.
2
Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.西班牙纳瓦拉 2022 年 1 月至 3 月，在 SARS-CoV-2 变异株奥密克戎 BA.1 为主的流行期间，接种疫苗的 COVID-19 病例住院和重症疾病风险降低。
Euro Surveill. 2023 Feb;28(5). doi: 10.2807/1560-7917.ES.2023.28.5.2200337.
本文引用的文献
1
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.在奥密克戎出现前后，芬兰老年人对严重 COVID-19 的疫苗有效性很高。
BMC Infect Dis. 2022 Nov 5;22(1):816. doi: 10.1186/s12879-022-07814-4.
2
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.mRNA 疫苗预防卡塔尔奥密克戎 BA.1 和 BA.2 亚变种对 SARS-CoV-2 的保护持续时间。
Nat Commun. 2022 Jun 2;13(1):3082. doi: 10.1038/s41467-022-30895-3.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎（B.1.1.529）和德尔塔（B.1.617.2）变异株的关系：一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.mRNA-1273 对 SARS-CoV-2 奥密克戎和德尔塔变异株的有效性。
Nat Med. 2022 May;28(5):1063-1071. doi: 10.1038/s41591-022-01753-y. Epub 2022 Feb 21.
5
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
6
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.尽管接种了mRNA疫苗加强针，但仍出现了新冠病毒奥密克戎变异株突破性感染。
Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.
7
Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021.基于真实世界监测数据估计的 COVID-19 疫苗对严重急性呼吸道感染（SARI）相关住院的有效性，斯洛文尼亚，2021 年 10 月。
Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101110.
8
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
9
Enhanced national surveillance of severe acute respiratory infections (SARI) within COVID-19 surveillance, Slovenia, weeks 13 to 37 2021.2021 年 COVID-19 监测期间，严重急性呼吸道感染（SARI）的强化国家监测，斯洛文尼亚，第 13 周至第 37 周。
Euro Surveill. 2021 Oct;26(42). doi: 10.2807/1560-7917.ES.2021.26.42.2100937.
Zotero 插件